Alterations in any of these RAS family genes is associated with poor patient prognosis in pan-cancer analyses (33, 34) (Figure 2E), and RAS pathway gene alterations frequently co-occur with the exception of KRAS-BRAF and KRAS-NRAS gene pairs, which are mutually exclusive (33, 34) (Figure 3). The gene discussed is KRAS; the disease is cancer.